![Michael Nohaile](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Nohaile
Direttore/Membro del Consiglio presso FULGENT GENETICS, INC.
Patrimonio netto: 285 059 $ in data 30/06/2024
Profilo
Michael Nohaile is currently the Chief Executive Officer at Prellis Biologics, Inc. and an Independent Director at Fulgent Genetics, Inc. He is also the Chief Scientific Officer at Generate Biomedicines, Inc. Dr. Nohaile's former positions include Director at Genoptix, Inc., Senior VP-Strategy, Commercialization & Innovation at Amgen, Inc., General Manager-Molecular Diagnostics Business at Novartis Corp., and Partner at McKinsey & Co., Inc. Dr. Nohaile received his undergraduate degree from Massachusetts Institute of Technology and his doctorate from the University of California, Berkeley.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
FULGENT GENETICS, INC.
0.05% | 16/05/2024 | 14 529 ( 0.05% ) | 285 059 $ | 30/06/2024 |
Posizioni attive di Michael Nohaile
Società | Posizione | Inizio |
---|---|---|
FULGENT GENETICS, INC. | Direttore/Membro del Consiglio | 01/08/2022 |
Generate Biomedicines, Inc.
![]() Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | Direttore Tecnico/Scientifico/R&S | - |
Prellis Biologics, Inc.
![]() Prellis Biologics, Inc. BiotechnologyHealth Technology Prellis Biologics, Inc. engages in building human tissues for drug development, and also develops human organs for transplantation. It offers vascularized tissue, bio and human organ printing. The firm's products include Organoid, Vascular Bundle, 3D Tissue Chip, Cell Seeding Matrix, Cell Adhesion Plus and Holograph-X Bioprinter. The company was founded by Noelle Huskey Mullin and Melanie Matheu in October 2016 and is headquartered in San Francisco, CA. | Amministratore Delegato | 11/08/2022 |
Precedenti posizioni note di Michael Nohaile
Società | Posizione | Fine |
---|---|---|
Novartis Corp.
![]() Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/11/2012 |
McKinsey & Co., Inc.
![]() McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2007 |
Genoptix, Inc.
![]() Genoptix, Inc. Medical SpecialtiesHealth Technology Genoptix, Inc. provides specialized oncology diagnostics services. It offers a range of customizable clinical trial, custom assay development and companion diagnostics development services. The company was founded in 1999 by Tina S. Nova and is headquartered in Carlsbad, CA. | Direttore/Membro del Consiglio | - |
AMGEN INC. | Corporate Officer/Principal | - |
Formazione di Michael Nohaile
University of California, Berkeley | Doctorate Degree |
Massachusetts Institute of Technology | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
AMGEN INC. | Health Technology |
FULGENT GENETICS, INC. | Health Services |
Aziende private | 5 |
---|---|
Novartis Corp.
![]() Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
McKinsey & Co., Inc.
![]() McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Generate Biomedicines, Inc.
![]() Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | Health Technology |
Prellis Biologics, Inc.
![]() Prellis Biologics, Inc. BiotechnologyHealth Technology Prellis Biologics, Inc. engages in building human tissues for drug development, and also develops human organs for transplantation. It offers vascularized tissue, bio and human organ printing. The firm's products include Organoid, Vascular Bundle, 3D Tissue Chip, Cell Seeding Matrix, Cell Adhesion Plus and Holograph-X Bioprinter. The company was founded by Noelle Huskey Mullin and Melanie Matheu in October 2016 and is headquartered in San Francisco, CA. | Health Technology |
Genoptix, Inc.
![]() Genoptix, Inc. Medical SpecialtiesHealth Technology Genoptix, Inc. provides specialized oncology diagnostics services. It offers a range of customizable clinical trial, custom assay development and companion diagnostics development services. The company was founded in 1999 by Tina S. Nova and is headquartered in Carlsbad, CA. | Health Technology |
- Borsa valori
- Insiders
- Michael Nohaile